CD8A and neoplasm: The antitumor efficacy of PD-1/PD-L1 blockers has been shown to correlate with an increased presence of CD8+ tumor-infiltrating lymphocytes and the overexpression of chemokines and cytokines in the tumor microenvironment (86).